Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose hrIL-2 in SLE
NCT02465580Phase 2Unknown
- Sponsor
- Peking University People's Hospital
- Start
- Jun 2015
- Primary completion
- Jun 2017
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing hrIL-2 active with hrIL-2 placebo (2 arms). Primary endpoints: SLE Responder Index at 24 weeks and Adverse Events and Serious Adverse Events at 24 weeks. Status: unknown.
02
Drugs
aldesleukin
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02465580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02465580.